|
|
 Previous Article | Table of Contents | Next Article 
Effects of recombinant erythropoietin on the concentration and cycling
status of human marrow hematopoietic progenitor cells in vivo
E Dessypris, SE Graber, SB Krantz and WJ Stone
Department of Medicine, Veterans Administration Medical Center.
The concentration of human marrow progenitors CFU-E, BFU-E, CFU-GM, and
CFU-Mk and the percentage of these progenitor cells in DNA synthesis were
studied in nine patients with transfusion-dependent anemia of end- stage
renal failure before and 2 weeks after treatment with human recombinant
erythropoietin (Epo) at a dose of 150 to 300 U/kg intravenously three times
per week. The concentration of CFU-E in the posttreatment marrow increased
by a mean of 4.15-fold, BFU-E by 3.37- fold, CFU-GM by 1.86-fold, and
CFU-Mk by 1.96-fold as compared with their respective concentrations in the
pretreatment marrows. This increase in the concentrations of marrow
progenitors was accompanied by almost a doubling of the percentage of these
cells in DNA synthesis as assessed by the 3H-thymidine suicide technique.
These observations demonstrate that at the progenitor cell level the human
marrow responds to therapeutic doses of Epo as an organ rather than by a
selective expansion of the erythroid cell line.
Volume 72,
Issue 6,
pp. 2060-2062,
12/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Borawski and M. Mysliwiec
Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients
Nephrol. Dial. Transplant.,
April 1, 2002;
17(4):
637 - 644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Stohlawetz, L. Dzirlo, N. Hergovich, E. Lackner, C. Mensik, H. G. Eichler, E. Kabrna, K. Geissler, and B. Jilma
Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans
Blood,
May 1, 2000;
95(9):
2983 - 2989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, F. Paoletti, S. Linari, C. Cellai, R. Caporale, P. R. Ferrini, M. Sanchez, G. Migliaccio, and A. R. Migliaccio
Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice
Blood,
April 15, 2000;
95(8):
2559 - 2568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Loo and Y. Beguin
The Effect of Recombinant Human Erythropoietin on Platelet Counts Is Strongly Modulated by the Adequacy of Iron Supply
Blood,
May 15, 1999;
93(10):
3286 - 3293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Pierelli, A. Perillo, S. Greggi, G. Salerno, P. B. Panici, G. Menichella, A. Fattorossi, G. Leone, S. Mancuso, and G. Scambia
Erythropoietin Addition to Granulocyte Colony-Stimulating Factor Abrogates Life-Threatening Neutropenia and Increases Peripheral-Blood Progenitor-Cell Mobilization After Epirubicin, Paclitaxel, and Cisplatin Combination Chemotherapy: Results of a Randomized Comparison
J. Clin. Oncol.,
April 1, 1999;
17(4):
1288 - 1288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Longmore, Y. You, J. Molden, K. D. Liu, A. Mikami, S. Y. Lai, P. Pharr, and M. A. Goldsmith
Redundant and Selective Roles for Erythropoietin Receptor Tyrosines in Erythropoiesis In Vivo
Blood,
February 1, 1998;
91(3):
870 - 878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Maier, M. Obladen, P. Scigalla, O. Linderkamp, G. Duc, G. Hieronimi, H. L. Halliday, H. T. Versmold, G. Moriette, G. Jorch, et al.
The Effect of Epoetin Beta (Recombinant Human Erythropoietin) on the Need for Transfusion in Very-Low-Birth-Weight Infants
N. Engl. J. Med.,
April 28, 1994;
330(17):
1173 - 1178.
[Abstract]
[Full Text]
|
|
|
|
|
